OCS — Oculis Holding AG Ordinary shares

OCS

SHORT CANDIDATENeutral

Composite

17.40

Technical

8.40

Fundamental

23.30

Rank

—

Price

7.63

Hurst

0.42

As of

Nov 4, 2026

Daily

Oculis Holding AG Ordinary shares

HEALTHCAREBIOTECHNOLOGY

Oculis Holding AG is a Swiss-based biopharmaceutical firm focused on creating topical therapeutic solutions for eye conditions affecting both the anterior and posterior regions of the eye. The company maintains its operations from its headquarters in Zug.

Market cap

$469.9M

P/E (trailing)

—

P/E (forward)

—

PEG ratio

—

Dividend yield

—

Beta

0.29

52w range

7.11 – 34.48

Return on equity

-43.70%

Profit margin

0.00%

Revenue growth

+18.80%

Earnings growth

0.00%

Price history

1Y: 7.63 (-60.4%) · range 7.17–32.65

Cycle position

20/ 100 cycle scoreENTRY ZONE

ENTRYAPPROACHMID-BULLNEAR-TOPEXIT

entry readiness 55 · MODERATE · exit proximity 0

Conviction

40/ 100 · maturity 14%

VScore.0919

Buildup.3038

EMA entry setup.3855

Fundamentals.2323

Volume profile

POC

11.22

Price vs POC

-32.0%

Overhead supply

96%

Runway

+47.1%

Value area 9.53–15.81 · 96% of 120d volume overhead · heavy supply

Get an AI analyst's read on this ticker.Open the AI analyst

Contributing sources

Source	Score	Last seen
earnings-surprise	0.967	Nov 4, 2026

Pattern & cluster

Pattern

NEUTRALdouble_bottom:forming

Cluster

NEUTRAL

Forward returns

Not yet labeled — the study prices these as positions mature.